Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 Dose Finding in Congestive Heart Failure
NCT03254108Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolvaptan in heart failure (HF) (5 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 1 and Area Under the Concentration-time Curve at Day 1. Started Nov 2017; status: completed.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03254108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254108.